American Journal of Health-System Pharmacy · 2009 · 14 citations · 2 references
PharmacyPharmaceuticsPharmacologyBioavailabilityOral Drug DeliveryPharmaceutical FormulationLiquid FormulationsPharmaceutical StabilitySolid Oral Dosage FormsStability Of Pharmaceutical FormulationsSuspension FormulationChild-resistant BottlesChild-resistant CapsDrug Product Shelf LifeGlass BottlesHigh-performance Liquid ChromatographyHigh-performance Liquid Chromatography AnalysisPlastic BottlesRoom-temperature Storage
PURPOSE: The stability of extemporaneously prepared moxifloxacin oral suspensions was studied. METHODS: An oral suspension of moxifloxacin 20 mg/mL was prepared by thoroughly grinding three 400-mg tablets of moxifloxacin in a glass mortar. Thirty milliliters of Ora-Plus and 30 mL of either Ora-Sweet or Ora-Sweet SF were mixed and added to the powder to make a final volume of 60 mL. Three identical samples of each formulation were prepared and placed in 2-oz amber plastic bottles with child-resistant caps and were stored at room temperature (23-25 degrees C). A 1-mL sample was withdrawn from each of the six bottles with a micropipette immediately after preparation and at 7, 14, 28, 60, and 90 days. After further dilution to an expected concentration of 8 microg/ mL with sample diluent, the samples were assayed in duplicate by stability-indicating high-performance liquid chromatography. Stability was defined as the retention of at least 90% of the initial concentration. RESULTS: At least 99% of the initial moxifloxacin remained throughout the 90-day study period in both preparations. There were no detectable changes in color, odor, taste, and pH and no visible microbial growth in any sample. CONCLUSION: Extemporaneously compounded suspensions of moxifloxacin 20 mg/mL in a 1:1 mixture of Ora-Plus and Ora-Sweet or Ora-Sweet SF were stable for at least 90 days when stored in 2-oz amber plastic bottles at room temperature.
2
M Córdoba-Borrego · Journal of Pharmaceutical and Biomedical Analysis · 1999 · 55 citations